Novel Precision Medicine Approach For Obesity Trial

Overview

About this study

The purpose of this study is to test the effectiveness of semaglutide 2.4 mg SQ weekly in patients with obesity with a positive MyPhenome test for abnormal postprandial satiety compared to patients with obesity with a negative MyPhenome test for abnormal postprandial satiety.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult men or women between 18 to 65 years with obesity (BMI ≥30 kg/m2) without or with controlled chronic conditions (e.g., controlled hypertension).

Exclusion Criteria:

  • Weight changes greater than 3% in the previous 3 months
  • History of bariatric surgery including lap band and bariatric endoscopy
  • Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) and Columbia Suicide Severity Rating Scale (C-SSRS[JS1] ). If such a dysfunction is identified by an anxiety or depression score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.  Any suicidal ideation of type 4 or 5, any suicide attempt during the patient’s lifetime, or any suicidal behavior in the last month.
  • Current use of anti-obesity medications or GLP1R agonists for Type 2 Diabetes
  • Any contraindication to FDA-approved GLP1R agonistsWomen who are pregnant or plan  to become pregnantOnce the positive or negative cohort is filled at 2:1 ratio, some patients will be screen failed if their gene cohort is full.
  • A family member who is enrolled in this study.
  • Principal Investigator discretion.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 02/03/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andres Acosta, M.D., Ph.D.

Open for enrollment

Contact information:

Megan Schaefer

(507) 266-6004

RSTINDIVOBESITY@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Maria Hurtado Andrade, M.D., Ph.D.

Contact us for the latest status

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available
.
CLS-20572286

Mayo Clinic Footer